A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer

NCT05725343 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

350

Enrollment

OTHER

Sponsor class

Stopped Novartis has decided to terminate the trial due to the recent results made available from the Novartis CANOPY A study (CACZ885T2301), this decision is not related to any safety data for Canakinumab

Conditions

Lung Cancer

Interventions

DRUG: Canakinumab
DRUG: Placebo

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

[object Object]